PMC:7784828 / 15643-18421 JSONTXT

{"project":"LitCovid-sentences","denotations":[{"id":"T132","span":{"begin":0,"end":2},"obj":"Sentence"},{"id":"T133","span":{"begin":4,"end":14},"obj":"Sentence"},{"id":"T134","span":{"begin":15,"end":215},"obj":"Sentence"},{"id":"T135","span":{"begin":216,"end":495},"obj":"Sentence"},{"id":"T136","span":{"begin":496,"end":659},"obj":"Sentence"},{"id":"T137","span":{"begin":660,"end":850},"obj":"Sentence"},{"id":"T138","span":{"begin":851,"end":1083},"obj":"Sentence"},{"id":"T139","span":{"begin":1084,"end":1200},"obj":"Sentence"},{"id":"T140","span":{"begin":1201,"end":1396},"obj":"Sentence"},{"id":"T141","span":{"begin":1397,"end":1554},"obj":"Sentence"},{"id":"T142","span":{"begin":1555,"end":1713},"obj":"Sentence"},{"id":"T143","span":{"begin":1714,"end":1863},"obj":"Sentence"},{"id":"T144","span":{"begin":1864,"end":2128},"obj":"Sentence"},{"id":"T145","span":{"begin":2129,"end":2284},"obj":"Sentence"},{"id":"T146","span":{"begin":2285,"end":2487},"obj":"Sentence"},{"id":"T147","span":{"begin":2488,"end":2586},"obj":"Sentence"},{"id":"T148","span":{"begin":2587,"end":2778},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"5. Conclusion\nIn summary, inefficient data sharing, irreproducibility of published work, high cost, high failure rates, and slow pace remain as significant challenges for the drug discovery and development process. Over the past few years, many research institutions around the world have developed an infrastructure in collaboration with pharma companies, peer research laboratories/institutions, government/philanthropy organizations to crowdsource resources, share knowledge and assess risk. The idea was mooted with the formation of the Academic Drug Discovery Consortium (ADCC) that aims at nurturing the academic drug discovery centers in the USA [46]. ADCC initiated a collaborative network to facilitate exchange of expertise and technical know-how, and the formation of partnerships among the participating organizations including industry. In addition to academic drug discovery centers, independent researchers around the globe have registered from various organizations, including universities, pharmaceutical companies, government institutions and diseases foundations. Many companies have also approached the ADDC for assistance in designing specific disease/ drug research areas [46]. The success of ADCC emphasizes the need for networking/ collaboration to harness the best possible avenues in the most cost-effective way for the rapid discovery of novel and effective medicines.\nVery recently, an unprecedented effort, as ever in the history, has been made to avert the COVID-19 pandemic by the National Institutes of Health (NIH) [47]. The NIH in collaboration with major drug companies and funders has announced a plan to conduct clinical trials employing drugs and vaccines to treat COVID-19. Priorities have been designated for testing and development of selected drugs/vaccines to avoid duplication and wastage of time, money and resources. The partnership called Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) is a collaborative network of NIH, government agencies in the U.S, pharma/biotech companies, academia and nonprofit Foundations of the National Institutes of Health (FNIH). ACTIV is defined as an international strategy to evaluate data on most promising early drug candidates for clinical trials by efficient use of NIH funding. The alliance will also study and analyze the genome of all SARS-CoV-2 strains, and how the virus infects various cell types and patients with different, underlining conditions, ages and genetic makeups. This is what the whole world looks forward to, a global alliance for the benefit of the humankind. Public–private partnerships, adaptive trial designs, and big data offers excellent avenues for innovating drug discovery and design process but face several challenges which must be met [27]."}

{"project":"LitCovid-PubTator","denotations":[{"id":"171","span":{"begin":2344,"end":2354},"obj":"Species"},{"id":"172","span":{"begin":2413,"end":2421},"obj":"Species"},{"id":"173","span":{"begin":1488,"end":1496},"obj":"Disease"},{"id":"174","span":{"begin":1704,"end":1712},"obj":"Disease"},{"id":"175","span":{"begin":1900,"end":1908},"obj":"Disease"}],"attributes":[{"id":"A171","pred":"tao:has_database_id","subj":"171","obj":"Tax:2697049"},{"id":"A172","pred":"tao:has_database_id","subj":"172","obj":"Tax:9606"},{"id":"A173","pred":"tao:has_database_id","subj":"173","obj":"MESH:C000657245"},{"id":"A174","pred":"tao:has_database_id","subj":"174","obj":"MESH:C000657245"},{"id":"A175","pred":"tao:has_database_id","subj":"175","obj":"MESH:C000657245"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"5. Conclusion\nIn summary, inefficient data sharing, irreproducibility of published work, high cost, high failure rates, and slow pace remain as significant challenges for the drug discovery and development process. Over the past few years, many research institutions around the world have developed an infrastructure in collaboration with pharma companies, peer research laboratories/institutions, government/philanthropy organizations to crowdsource resources, share knowledge and assess risk. The idea was mooted with the formation of the Academic Drug Discovery Consortium (ADCC) that aims at nurturing the academic drug discovery centers in the USA [46]. ADCC initiated a collaborative network to facilitate exchange of expertise and technical know-how, and the formation of partnerships among the participating organizations including industry. In addition to academic drug discovery centers, independent researchers around the globe have registered from various organizations, including universities, pharmaceutical companies, government institutions and diseases foundations. Many companies have also approached the ADDC for assistance in designing specific disease/ drug research areas [46]. The success of ADCC emphasizes the need for networking/ collaboration to harness the best possible avenues in the most cost-effective way for the rapid discovery of novel and effective medicines.\nVery recently, an unprecedented effort, as ever in the history, has been made to avert the COVID-19 pandemic by the National Institutes of Health (NIH) [47]. The NIH in collaboration with major drug companies and funders has announced a plan to conduct clinical trials employing drugs and vaccines to treat COVID-19. Priorities have been designated for testing and development of selected drugs/vaccines to avoid duplication and wastage of time, money and resources. The partnership called Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) is a collaborative network of NIH, government agencies in the U.S, pharma/biotech companies, academia and nonprofit Foundations of the National Institutes of Health (FNIH). ACTIV is defined as an international strategy to evaluate data on most promising early drug candidates for clinical trials by efficient use of NIH funding. The alliance will also study and analyze the genome of all SARS-CoV-2 strains, and how the virus infects various cell types and patients with different, underlining conditions, ages and genetic makeups. This is what the whole world looks forward to, a global alliance for the benefit of the humankind. Public–private partnerships, adaptive trial designs, and big data offers excellent avenues for innovating drug discovery and design process but face several challenges which must be met [27]."}